Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial

BACKGROUND: Anticoagulation in patients with malignancy and atrial fibrillation is challenging because of enhanced risks for thrombosis and bleeding and the frequent need for invasive procedures. Data on direct oral antagonists in such patients are sparse. METHODS AND RESULTS: The ENGAGE AF‐TIMI 48...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: Fanola, Christina L., Ruff, Christian T., Murphy, Sabina A., Jin, James, Duggal, Anil, Babilonia, Noe A., Sritara, Piyamitr, Mercuri, Michele F., Kamphuisen, Pieter W., Antman, Elliott M., Braunwald, Eugene, Giugliano, Robert P.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201390/
https://ncbi.nlm.nih.gov/pubmed/30369307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.008987
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars